579 related articles for article (PubMed ID: 22780968)
21. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
22. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
23. [Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response].
Zou WY; Xu DR; Su C; Chen M; Li J; Luo SK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1868-70, 1873. PubMed ID: 20813688
[TBL] [Abstract][Full Text] [Related]
24. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
[TBL] [Abstract][Full Text] [Related]
25. Bcr-Abl induces autocrine IGF-1 signaling.
Lakshmikuttyamma A; Pastural E; Takahashi N; Sawada K; Sheridan DP; DeCoteau JF; Geyer CR
Oncogene; 2008 Jun; 27(27):3831-44. PubMed ID: 18246120
[TBL] [Abstract][Full Text] [Related]
26. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells.
Gutiérrez P; Delgado MD; Richard C; Moreau-Gachelin F; León J
Biochem Biophys Res Commun; 1997 Nov; 240(3):862-8. PubMed ID: 9398659
[TBL] [Abstract][Full Text] [Related]
27. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
28. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
[TBL] [Abstract][Full Text] [Related]
29. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
30. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
31. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
Ortmann CA; Burchert A; Hölzle K; Nitsche A; Wittig B; Neubauer A; Schmidt M
Nucleic Acids Res; 2005; 33(21):6895-905. PubMed ID: 16396836
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
35. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
37. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
Li Z; Luo J
Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
[TBL] [Abstract][Full Text] [Related]
38. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
39. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
40. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
